{"type":"trials","record":{"id":28332,"source_id":"clinicaltrials-gov","external_id":"NCT06635148","title":"A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","brief_summary":"The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.","overall_status":"Recruiting","phases":["PHASE2","PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Janssen Research & Development, LLC","enrollment":274,"countries":["United States","Australia","Belgium","Canada","China","Czechia","Denmark","Germany","Hungary","Italy","Netherlands","Poland","Portugal","Spain","Sweden","Switzerland","Turkey (Türkiye)","United Kingdom"],"start_date":"2024-09-19","completion_date":"2030-07-16","last_update_date":"2026-09-14","source_url":"https://clinicaltrials.gov/study/NCT06635148","editorial_summary":"A registered PHASE2, PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T00:17:13.08831+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"60 Years","comparator":null,"organization":"Janssen Research & Development, LLC","interventions":["JNJ-81201887","Sham Procedure"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of Participants with Ocular and Systemic Treatment-emergent Adverse Events (TEAEs) — Upto 5 Years","Number of Participants with Abnormal Findings in Clinical Laboratory Assessments — Upto 5 Years","Number of Participants with Abnormal Findings in Retinal imaging and Eye Examinations — Upto 5 Years","Change from Baseline in Best Corrected Visual Acuity (BCVA) Using Early Treatment Diabetic Retinopathy Study (ETDRS) Le…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","source_has_results":false},"controlled_terms":["Geographic Atrophy","Macular Degeneration","JNJ-81201887","Sham Procedure"],"relevance_confidence":80,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06635148","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2024-09-19 to 2030-07-16","comparator":null,"confidence":"structured-source","population":"ALL · 60 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.797Z","intervention":["JNJ-81201887","Sham Procedure"],"participants":274,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2, PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of Participants with Ocular and Systemic Treatment-emergent Adverse Events (TEAEs) — Upto 5 Years","Number of Participants with Abnormal Findings in Clinical Laboratory Assessments — Upto 5 Years","Number of Participants with Abnormal Findings in Retinal imaging and Eye Examinations — Upto 5 Years","Change from Baseline in Best Corrected Visual Acuity (BCVA) Using Early Treatment Diabetic Retinopathy Study (ETDRS) Le…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/28332","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}